日韩A∨无码成人精品国产,激情A片久久久久久久,无码天堂va亚洲va在线va免费无码又爽又刺激高潮虎虎视频,伊人无码精品久久一区二区,婷婷激情五月一区二区三区播放中美女 赤裸 一区二区三区,精品亚洲成A人片在线观看少妇,亚洲欧美综合国产不卡,国产精品亚洲а∨天堂免

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
亚洲人成绝费网站色www吃脚| 成人H无码动漫在线观看| 国产女人爽的流水毛片| 亚洲AV日韩AV无码偷拍| 欧美大片欧美激情性色a∨在线| 无码专区狠狠躁躁天天躁| 亚洲永久网址在线观看| 日韩欧美精品一区二区三区视频在线观看| 蜜臀98精品国产免费观看| 久久久久亚洲AV成人网人人网站| 久久国产天堂福利天堂| 中文综合无码一区二区三区| 久久99人妻无码精品一区二区| 亚洲av永久无码精品秋霞电影影院| 国产无码专区在线播放视频| 国产真实老熟女无套内射| 精品无码av一区二区三区不卡| 麻豆导演中出人妻| 国产成人影院一区二区三区| 欧美性群另类交| 嘿咻视频无码免费区在线观看| 久久精品免视看国产成人不卡| 亚洲人成无码A片在线观看| 国产成人精品久久亚洲高清不卡p| 国产日韩欧美拔插一区| 亚洲欧美国产va在线播放频| 欧美裸体XXXX极品少妇| 九九99久久精品在免费线bt国内精品伊人久久久久| 国产成人一区在线播放| 久久无码av一区二区三区电影网| 天堂久久久久va久久久久| 国产成人精品a视频一区| 2021国产v亚洲v天堂无码| 99精品电影一区二区免费看| 最近日本中文字幕免费| 五月天中文字幕MV在线| 日韩精品极品视频在线观看免费| 97精品人妻一区二区三区香蕉| 国产经典一区二区三区| 中文字幕一区二区AⅤ无码| 成人亚洲一区二区三区在线|